Form 4: Forte Biosciences CFO Reports Stock Transactions
SEC Form 4 Filing
Antony A. Riley, CFO of Forte Biosciences, reports the vesting and subsequent disposal of shares to cover tax obligations.
Summary
- On January 1, 2025, Antony A. Riley, the CFO of Forte Biosciences, had 375 restricted stock units (RSUs) vest.
- These RSUs converted into common stock.
- Simultaneously, 154 shares were disposed of at a price of $22.71 to cover tax obligations.
- Following these transactions, Riley directly owns 30,997 shares of Forte Biosciences common stock and 3,000 RSUs.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and stock transactions, with no inherent positive or negative implications for the company's overall prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is crucial for investor confidence and market efficiency.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the vesting of previously granted equity compensation.
- The disposal of shares to cover taxes has no material impact on the company's financials.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | One-sixteenth of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. |
| 01/01/2025 | Date of transaction: vesting of 375 Restricted Stock Units and disposal of 154 shares for tax obligations. |
| 01/02/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.